Ketek's Political Fallout
This article was originally published in RPM Report
Executive Summary
The negative attention from Capitol Hill over the approval of the antibiotic Ketek is impacting much more than the commercial prospects of a single drug: it's making FDA reviewers think twice about other applications.
You may also be interested in...
‘FDA Is Not the Villain:’ Study Highlights Need For Post-Market Focus To Spur Antibiotics
A study of drug approvals over more than three decades shows antimicrobials, including antibacterials, had consistently shorter development and review times than other types of products. While antibacterials were less likely to participate in special US FDA programs designed to help along review, experts said reimbursement reform, not new regulatory flexibility, is needed to help address the crisis of drug-resistant infections.
GAIN Begins (Part 1): FDA Completes Turnaround On Antibiotic R&D
In less than two years, FDA has moved from requiring unrealistic approval standards for antibiotics to exploring innovative ways to shorten the pathway for the most-needed drugs. And, surprise: Congress is on board too. After 15 years, there is finally real momentum on antibiotic drug policy. But is it all enough to get companies back in the game?
Data Integrity Delays: Another Key Takeaway from Ketek
Senator Grassley wants FDA to withhold NDAs from advisory committees if there are pending questions about the authenticity of any of the clinical data. The agency appears to agree. That could represent another roadblock to NDA reviews.